Publications
2024
Tissue gene expression profiles and communication networks inform candidate blood biomarker identification in psoriasis and atopic dermatitis.
Soul, J., Carlsson, E., Hofmann, S. R., Russ, S., Hawkes, J., Schulze, F., . . . Hedrich, C. M. (2024). Tissue gene expression profiles and communication networks inform candidate blood biomarker identification in psoriasis and atopic dermatitis.. Clinical immunology (Orlando, Fla.), 265, 110283. doi:10.1016/j.clim.2024.110283
2023
Urinary markers of the alternative and lectin complement pathway are increased in IgA vasculitis nephritis.
Marro, J., Chetwynd, A. J., Hawkes, J., Northey, S. J., & Oni, L. (2023). Urinary markers of the alternative and lectin complement pathway are increased in IgA vasculitis nephritis.. Clinical kidney journal, 16(12), 2703-2711. doi:10.1093/ckj/sfad236
Neutrophil function following treatment of psoriatic arthritis patients with secukinumab: altered cytokine signalling but no impairment of host defence
Cross, A., Hawkes, J., Frankland, H., Mediana, A., Wright, H., Goodson, N., . . . Moots, R. (2023). Neutrophil function following treatment of psoriatic arthritis patients with secukinumab: altered cytokine signalling but no impairment of host defence. Rheumatology. doi:10.1093/rheumatology/kead007
2020
APPA (apocynin and paeonol) modulates pathological aspects of human neutrophil function, without supressing antimicrobial ability, and inhibits TNFα expression and signalling
Cross, A. L., Hawkes, J., Wright, H. L., Moots, R. J., & Edwards, S. W. (2020). APPA (apocynin and paeonol) modulates pathological aspects of human neutrophil function, without supressing antimicrobial ability, and inhibits TNFα expression and signalling. INFLAMMOPHARMACOLOGY, 28(5), 1223-1235. doi:10.1007/s10787-020-00715-5
SECUKINUMAB THERAPY DOES NOT AFFECT NEUTROPHIL HOST DEFENCE IN PSORIATIC ARTHRITIS
Cross, A., Hawkes, J., Frankland, H., Mediana, A., Wright, H., Goodson, N., . . . Moots, R. (2020). SECUKINUMAB THERAPY DOES NOT AFFECT NEUTROPHIL HOST DEFENCE IN PSORIATIC ARTHRITIS. In ANNALS OF THE RHEUMATIC DISEASES Vol. 79 (pp. 1353-1354). doi:10.1136/annrheumdis-2020-eular.4477
2019
014 APPA inhibits neutrophil pro-inflammatory functions without impairing host defence: is this a potential new therapy for arthritis?
Cross, A. L., Hawkes, J. J., Wright, H. L., Moots, R. J., & Edwards, S. W. (2019). 014 APPA inhibits neutrophil pro-inflammatory functions without impairing host defence: is this a potential new therapy for arthritis?. Rheumatology, 58(Supplement_3). doi:10.1093/rheumatology/kez106.013
APPA, A POTENTIAL NEW THERAPY FOR OSTEOARTHRITIS, INHIBITS NEUTROPHIL PRO-INFLAMMATORY FUNCTIONS WITHOUT IMPAIRING HOST DEFENCE
Cross, A., Hawkes, J., Wright, H., Larkins, N., Edwards, S., & Moots, R. (2019). APPA, A POTENTIAL NEW THERAPY FOR OSTEOARTHRITIS, INHIBITS NEUTROPHIL PRO-INFLAMMATORY FUNCTIONS WITHOUT IMPAIRING HOST DEFENCE. In OSTEOARTHRITIS AND CARTILAGE Vol. 27 (pp. S189-S190). doi:10.1016/j.joca.2019.02.290
APPA INHIBITS NEUTROPHIL PRO-INFLAMMATORY FUNCTIONS WITHOUT IMPAIRING HOST DEFENCE: IS THIS A POTENTIAL NEW THERAPY FOR ARTHRITIS?
Cross, A. L., Hawkes, J. J., Wright, H. L., Moots, R. J., & Edwards, S. W. (2019). APPA INHIBITS NEUTROPHIL PRO-INFLAMMATORY FUNCTIONS WITHOUT IMPAIRING HOST DEFENCE: IS THIS A POTENTIAL NEW THERAPY FOR ARTHRITIS?. In RHEUMATOLOGY Vol. 58 (pp. 46). Retrieved from https://www.webofscience.com/
2016
EFFECTS OF APPA ON HUMAN NEUTROPHIL FUNCTION
Cross, A., Hawkes, J., Moots, R., & Nicholas, L. (2016). EFFECTS OF APPA ON HUMAN NEUTROPHIL FUNCTION. OSTEOARTHRITIS AND CARTILAGE, 24, S335-S336. doi:10.1016/j.joca.2016.01.601
2014
236. Microparticle Micrornas Correlate with Disease Activity in Rheumatoid Arthritis and May Play a Significant Role in Pathogenesis
Bishop, K., Winget, C., Cross, A., Barnes, T., Hawkes, J., Moots, R., . . . Edwards, S. (2014). 236. Microparticle Micrornas Correlate with Disease Activity in Rheumatoid Arthritis and May Play a Significant Role in Pathogenesis. Rheumatology, 53(suppl_1), i148. doi:10.1093/rheumatology/keu117.005